How Gland Pharma Jumped 15% to Hit a 52-Week High A Story of Strong Q4 Results and Margin Expansion

Gland Pharma shares surged 14.67% to ₹2,142.30 on NSE hitting a 52-week high. Just a year ago the stock was at its 52-week low of ₹1,452.20. A strong Q4 FY26 earnings report drove this sharp reversal. Net profit → ₹366.67 crore (up 96.56% YoY from ₹186.54 crore) Revenue → up 22.3% YoY EBITDA → ₹513 crore (up 48% YoY) EBITDA margin → expanded to 29% from 24% a year ago Dividend → ₹20 per share recommended for FY26 Capacity expansion→ New manufacturing capacity coming online allowed Gland to produce and sell more products. New product ramp up → Fresh product launches contributed to revenue growth beyond existing products. Cost optimisation → Contract renegotiations and cost control measures improved margins meaning more profit from every rupee of revenue earned. Operating leverage → As revenue grew, fixed costs got spread over a larger base naturally boosting margins from 24% to 29%. When a company grows revenue without proportionally increasing its fixed costs, profits grow faster than revenue. This is called operating leverage.

Gland Pharma's EBITDA grew 48% even though revenue grew only 22% a classic example of operating leverage at work. Track new product approvals and capacity utilisation in coming quarters. If Gland maintains margin expansion above 28% in FY27, the stock could sustain its momentum. Gland Pharma's 15% single day rally after reporting a 96% profit jump teaches investors that strong earnings surprises combined with margin expansion are the most powerful drivers of short-term stock price movement, and that understanding operating leverage how profits grow faster than revenue when costs are controlled is a key skill for identifying high quality pharma stocks before they break out.